News

HMP Global Learning Network
hmpgloballearningnetwork.com > site > frmc > videos > first-line-immunotherapy-advanced-squamous-cell-carcinoma-anal-canal-scac-evidence

First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review

4+ hour, 37+ min ago  (259+ words) Al B. Benson III, MD, FACP, FACCC, FASCO, is a professor of medicine in the Division of Hematology/Oncology at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. He is also the associate director for Cooperative Groups at the Robert…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > transplant-vs-car-t-therapy-newly-diagnosed-transplant-eligible-multiple-myeloma

Transplant vs CAR-T Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma

5+ hour, 57+ min ago  (352+ words) At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Kenneth Shain, MD, PhD, Moffitt Cancer Center, Tampa, Florida explores transplant versus CAR-T therapy in the context of newly diagnosed transplant-eligible patients with multiple myeloma (MM)." My name is Ken Shain....

HMP Global Learning Network
hmpgloballearningnetwork.com > site > emsworld > videos > pediatric-video-tutorial-hemophilia-types-treatments-take-2

Pediatric Video Tutorial: Hemophilia Types & Treatments Take 2

7+ hour, 32+ min ago  (309+ words) Pediatric Video Tutorial: Hemophilia Types & Treatments Take 2hmpgloballearningnetwork.com Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. - h415.hmpgloballearningnetwork.com 2 AWSALB [x2]Registers which server-cluster is serving the visitor. This is used in…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > achieving-optimal-skin-and-itch-targets-drives-superior-quality-life-outcomes

Achieving Optimal Skin and Itch Targets Drives Superior Quality-of-Life Outcomes in Atopic Dermatitis

1+ day, 2+ hour ago  (16+ words) Achieving Optimal Skin and Itch Targets Drives Superior Quality-of-Life Outcomes in Atopic Dermatitis'hmpgloballearningnetwork.com...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > upadacitinib-achieves-consistent-skin-clearance-across-body-regions-real-world-ad

Upadacitinib Achieves Consistent Skin Clearance Across Body Regions in Real-World AD-VISE Study

1+ day, 3+ hour ago  (332+ words) Upadacitinib Achieves Consistent Skin Clearance Across Body Regions in Real-World AD-VISE Study'hmpgloballearningnetwork.com Upadacitinib Achieves Consistent Skin Clearance Across Body Regions in Real-World AD-VISE Study A real-world analysis from the AD-VISE study demonstrates that upadacitinib delivers consistent improvements in skin…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > risankizumab-maintains-radiographic-nonprogression-through-5-years-psoriatic

Risankizumab Maintains Radiographic Nonprogression Through 5 Years in Psoriatic Arthritis

1+ day, 3+ hour ago  (290+ words) Five-year data from the phase 3 KEEPsAKE 1 trial show that risankizumab maintains low rates of radiographic progression in patients with active psoriatic arthritis (PsA), supporting its role in long-term structural disease control. "In patients with psoriatic arthritis (PsA), chronic inflammation in…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > icotrokinra-delivers-consistent-skin-clearance-across-exposure-levels-phase-3

Icotrokinra Delivers Consistent Skin Clearance Across Exposure Levels in Phase 3 Psoriasis Analysis

1+ day, 3+ hour ago  (288+ words) Phase 3 exposure-response analyses demonstrate that icotrokinra, an oral IL-23 receptor inhibitor, provides consistent and robust skin clearance in patients with moderate-to-severe plaque psoriasis, with stable efficacy across exposure levels and a favorable safety profile. "Plaque psoriasis is a chronic inflammatory skin…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > upadacitinib-demonstrates-consistent-long-term-safety-across-age-groups-atopic

Upadacitinib Demonstrates Consistent Long-Term Safety Across Age Groups in Atopic Dermatitis Over 6 Years

1+ day, 3+ hour ago  (263+ words) An integrated safety analysis from 3 phase 3 trials suggests that upadacitinib maintains a consistent long-term safety profile for patients with moderate-to-severe atopic dermatitis (AD), with follow-up extending up to 6 years across global and US populations. The investigators noted, "6 years of long-term…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > jic > conference-coverage > national-trends-aortic-stenosis-mortality-pre-and-post-tavr-eras

National Trends in Aortic Stenosis Mortality in the Pre- and Post-TAVR Eras in the United States, 1999 to 2023

16+ hour, 22+ min ago  (843+ words) Interview by Laura Simson, MA In this interview with JIC, Dr Saad Ur Rahman discusses findings from "National Trends in Aortic Stenosis Mortality in the Pre- and Post-TAVR Eras in the United States 19992023," presented at the 2026 American College of Cardiology…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > news > upadacitinib-delivers-rapid-sustained-improvements-severe-atopic-dermatitis-real

Upadacitinib Delivers Rapid, Sustained Improvements in Severe Atopic Dermatitis in Real-World Cohort

1+ day, 3+ hour ago  (236+ words) A real-world retrospective cohort study suggests that upadacitinib provides meaningful and sustained clinical improvement in patients with severe atopic dermatitis (AD), including those with prior systemic and biologic treatment exposure and involvement of difficult anatomical sites. "Severe AD involving special…...